These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 21521273)

  • 21. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
    Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
    Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
    Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
    Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papillary thyroid carcinoma in children: risk factors and complications of disease recurrence.
    Palmer BA; Zarroug AE; Poley RN; Kollars JP; Moir CR
    J Pediatr Surg; 2005 Aug; 40(8):1284-8. PubMed ID: 16080933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The surgical treatment and prognostic factors of well-differentiated thyroid cancers in Chinese patients: a 20-year experience.
    Tseng LM; Lee CH; Wang HC; Shyr YM; Chiu JH; Wu CW; Lui WY; P'eng FK
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Aug; 58(2):121-31. PubMed ID: 8915115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical recurrence of papillary thyroid cancer in the remnant lobe.
    Asanuma K; Kobayashi S; Sugenoya A; Yokoyama S; Shingu K; Hama Y; Itoh N; Kasuga Y; Amano J
    Eur J Surg; 2000 Mar; 166(3):202-6. PubMed ID: 10755332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
    Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
    J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence.
    Chu KP; Baker S; Zenke J; Morad A; Ghosh S; Morrish DW; McEwan AJBS; Williams DC; Severin D; McMullen TPW
    Thyroid; 2018 Jul; 28(7):902-912. PubMed ID: 29742993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period.
    Hay ID; Hutchinson ME; Gonzalez-Losada T; McIver B; Reinalda ME; Grant CS; Thompson GB; Sebo TJ; Goellner JR
    Surgery; 2008 Dec; 144(6):980-7; discussion 987-8. PubMed ID: 19041007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural history, treatment, and course of papillary thyroid carcinoma.
    DeGroot LJ; Kaplan EL; McCormick M; Straus FH
    J Clin Endocrinol Metab; 1990 Aug; 71(2):414-24. PubMed ID: 2380337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation.
    Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Moon DH; Sung TY; Yoon JH; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3695-700. PubMed ID: 21976723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance.
    Durante C; Montesano T; Torlontano M; Attard M; Monzani F; Tumino S; Costante G; Meringolo D; Bruno R; Trulli F; Massa M; Maniglia A; D'Apollo R; Giacomelli L; Ronga G; Filetti S;
    J Clin Endocrinol Metab; 2013 Feb; 98(2):636-42. PubMed ID: 23293334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group.
    La Quaglia MP; Black T; Holcomb GW; Sklar C; Azizkhan RG; Haase GM; Newman KD
    J Pediatr Surg; 2000 Jun; 35(6):955-9; discussion 960. PubMed ID: 10873043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
    Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
    Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
    Grigsby PW; Reddy RM; Moley JF; Hall BL
    Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy.
    Cohn KH; Bäckdahl M; Forsslund G; Auer G; Zetterberg A; Lundell G; Granberg PO; Löwhagen T; Willems JS; Cady B
    Surgery; 1984 Dec; 96(6):957-71. PubMed ID: 6505969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study.
    Pelttari H; Välimäki MJ; Löyttyniemi E; Schalin-Jäntti C
    Eur J Endocrinol; 2010 Nov; 163(5):757-63. PubMed ID: 20813788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
    Mihailovic J; Nikoletic K; Srbovan D
    J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.